Gilead Release: Multiple Provinces Align To Provide Public Funding For Harvoni, The First Single Tablet Regimen For The Treatment Of Genotype 1 Chronic Hepatitis C Virus Infection

MISSISSAUGA, Ontario--(BUSINESS WIRE)--Gilead Sciences Canada, Inc. (Gilead Canada) today announced that multiple provinces will provide public access to Harvoni™ (ledipasvir/sofosbuvir), the first once-daily, single tablet regimen for the treatment of chronic hepatitis C virus (HCV) genotype 1 infection in adults. In Canada, it is estimated that more than 250,000 Canadians are living with chronic HCV infection, with thousands of new cases diagnosed each year.1 Genotype 1 infection represents an estimated 65 per cent of patient cases.2

Help employers find you! Check out all the jobs and post your resume.